Limits...
The effect of interleukin 36 gene therapy in the regression of tumor.

Solahaye-Kahnamouii S, Farhadi F, Rahkare-Farshi M, Pakdel F, Kashefimehr A, Pouralibaba F, Shirani G, Bayat M, Karimi A - Iran J Cancer Prev (2014)

Bottom Line: In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.

ABSTRACT

Background: Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors and is one of the cancer treatment strategies. Recently, interluekin36 (IL36) has been used as immunotherapeutic agents in cancer gene therapy. Present study investigated that the IL36 gene therapy effects on the regression of tumor masses in mouse model. Aim of this study is determination of the gene therapy effects by IL36 in the regression of tumor masses in mouse model.

Methods: To study the therapeutic efficacy of this cytokine, WEHI-164 tumor cells were transected with mIL36 plasmids. ELISA test was used to check cytokine production by transected cells. To establish fibro sarcoma mouse model, Tumoral transfected cells were injected subcutaneously to inoculate tumor in BALB/C mice. Tumor volumes were measured by caliper. Mice were sacrificed and tumors were extracted. The expression of IL36 and IFN-γ was studied with Real-time PCR and immunoblotting. The expression of Ki-67 (a tumor proliferation marker) in tumor masses was studied by immunohistochemistry staining. In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.

Results: The group treated with IL36 indicated decrease of tumor mass volume (p<0.001). The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).

Conclusion: Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36. IL36 gene therapy has therapeutic effects on the regression of tumor masses in fibro sarcoma mouse model.

No MeSH data available.


Related in: MedlinePlus

IL36 induces proliferation, production of IFN-γ and enhanced cytotoxic activity of these cells and induces the polarization of CD4+ T cells to the Th1 phenotype that mediates immunity against intracellular pathogens. IL36, especially in combination with IL-18, also acts on macrophages and dendritic cells to induce IFN-γ production even in antigen presenting cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4307102&req=5

f1-IJCP-07-197: IL36 induces proliferation, production of IFN-γ and enhanced cytotoxic activity of these cells and induces the polarization of CD4+ T cells to the Th1 phenotype that mediates immunity against intracellular pathogens. IL36, especially in combination with IL-18, also acts on macrophages and dendritic cells to induce IFN-γ production even in antigen presenting cells.

Mentions: Enzyme-Linked Immunosorbent Assay (ELISA) test was used for confirmation of IL36 production by tumor transected cell. The concentration of IL36 in supernatant of tumor transected cell culture was assessed by spectrophotometer in 540 nm λ. The IL36 concentration in the supernatant of the tumor transected cell culture was 1000 pg/m9l (figure1).


The effect of interleukin 36 gene therapy in the regression of tumor.

Solahaye-Kahnamouii S, Farhadi F, Rahkare-Farshi M, Pakdel F, Kashefimehr A, Pouralibaba F, Shirani G, Bayat M, Karimi A - Iran J Cancer Prev (2014)

IL36 induces proliferation, production of IFN-γ and enhanced cytotoxic activity of these cells and induces the polarization of CD4+ T cells to the Th1 phenotype that mediates immunity against intracellular pathogens. IL36, especially in combination with IL-18, also acts on macrophages and dendritic cells to induce IFN-γ production even in antigen presenting cells.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4307102&req=5

f1-IJCP-07-197: IL36 induces proliferation, production of IFN-γ and enhanced cytotoxic activity of these cells and induces the polarization of CD4+ T cells to the Th1 phenotype that mediates immunity against intracellular pathogens. IL36, especially in combination with IL-18, also acts on macrophages and dendritic cells to induce IFN-γ production even in antigen presenting cells.
Mentions: Enzyme-Linked Immunosorbent Assay (ELISA) test was used for confirmation of IL36 production by tumor transected cell. The concentration of IL36 in supernatant of tumor transected cell culture was assessed by spectrophotometer in 540 nm λ. The IL36 concentration in the supernatant of the tumor transected cell culture was 1000 pg/m9l (figure1).

Bottom Line: In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Oral Maxillofacial Surgery, Tehran University of Medical Science, Tehran, Iran.

ABSTRACT

Background: Cancer immunotherapy attempts to stimulate the immune system to reject and destroy tumors and is one of the cancer treatment strategies. Recently, interluekin36 (IL36) has been used as immunotherapeutic agents in cancer gene therapy. Present study investigated that the IL36 gene therapy effects on the regression of tumor masses in mouse model. Aim of this study is determination of the gene therapy effects by IL36 in the regression of tumor masses in mouse model.

Methods: To study the therapeutic efficacy of this cytokine, WEHI-164 tumor cells were transected with mIL36 plasmids. ELISA test was used to check cytokine production by transected cells. To establish fibro sarcoma mouse model, Tumoral transfected cells were injected subcutaneously to inoculate tumor in BALB/C mice. Tumor volumes were measured by caliper. Mice were sacrificed and tumors were extracted. The expression of IL36 and IFN-γ was studied with Real-time PCR and immunoblotting. The expression of Ki-67 (a tumor proliferation marker) in tumor masses was studied by immunohistochemistry staining. In this study we had 2 groups which are treated with IL-36 and Untreated with IL-36 as a blank.

Results: The group treated with IL36 indicated decrease of tumor mass volume (p<0.001). The results of western blotting and real-time PCR showed the IL36 expression increased in the group treated with IL36 (with relative expression of 1.9).

Conclusion: Immunohistochemistry staining indicated that the Ki-67expression has been reduced in the group interfered with IL36. IL36 gene therapy has therapeutic effects on the regression of tumor masses in fibro sarcoma mouse model.

No MeSH data available.


Related in: MedlinePlus